CD19 is a marker for B cells, the white blood cells responsible for producing antibodies. It appears on the surface of B cells at nearly every stage of their development, making it one of the most reliable identifiers of this cell lineage in both routine blood work and cancer diagnosis. In healthy adults, CD19-positive cells typically make up 6 to 20 percent of circulating lymphocytes, with absolute counts ranging from about 96 to 515 cells per microliter of blood.
Why CD19 Identifies B Cells So Reliably
CD19 is a protein embedded in the outer membrane of B cells. It first appears early in B-cell development, around the time a young B cell begins rearranging its antibody genes in the bone marrow. From that point forward, CD19 stays on the cell surface through every subsequent stage of maturation, including the memory B cells that circulate in your blood for years after an infection or vaccination.
The one exception is the very last stage. When a B cell fully matures into a plasma cell, the antibody-producing factory of the immune system, it loses CD19 expression. This makes CD19 useful for distinguishing between B cells that are still developing or circulating and plasma cells that have reached their final form. The protein’s density on the cell surface is tightly regulated throughout this journey, rising and falling at different developmental stages but never disappearing entirely until that terminal switch.
Functionally, CD19 does more than just sit on the surface as a label. It forms a complex with other membrane proteins that lowers the threshold for B-cell activation. In practical terms, CD19 makes it easier for a B cell to respond when it encounters something foreign. It does this by amplifying the signaling cascade that begins when an antigen binds to the B-cell receptor, triggering a chain of internal signals that ultimately releases calcium stores inside the cell and activates growth pathways.
CD19 in Blood Cancer Diagnosis
When doctors suspect a blood cancer, one of the first tests they order is flow cytometry, a technique that identifies cells based on the proteins on their surface. CD19 is a cornerstone of this process. Because B cells almost never lose CD19 when they become cancerous, the protein reliably flags malignancies that originate from the B-cell lineage.
The cancers most commonly identified through CD19 include B-cell acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and many types of non-Hodgkin lymphoma. In these diseases, the abnormal cells carry CD19 just as their healthy counterparts would, which helps pathologists confirm the cancer’s origin. Interestingly, a subset of acute myeloid leukemias, cancers that arise from a different cell lineage entirely, also express CD19, hinting at the close developmental relationship between lymphoid and myeloid cells in the bone marrow.
CD19 also plays a diagnostic role in multiple myeloma, though the relationship is more nuanced. Mature myeloma cells are plasma cells and generally lack CD19. However, about 3 percent of the cancerous plasma cell population in myeloma patients consists of less differentiated, stem-like cells that still carry CD19. Research from the Spanish Myeloma Group has shown that these CD19-positive progenitor cells tend to resist standard treatments and persist even after effective initial therapy. Detecting them through flow cytometry correlates with a worse prognosis, making CD19 a meaningful marker even in a cancer where most cells have lost it.
CD19 as a Target for Immunotherapy
The same features that make CD19 a good diagnostic marker also make it an appealing target for treatment. It is present on cancer cells but absent from the blood-forming stem cells in the bone marrow, which means therapies aimed at CD19 can destroy cancerous B cells without wiping out the stem cells needed to rebuild the immune system afterward.
The most well-known CD19-targeted treatments are CAR-T cell therapies. In this approach, a patient’s own T cells are removed, genetically engineered to recognize CD19, and infused back into the body. Several of these therapies have received FDA approval for B-cell cancers, with the most recent being obecabtagene autoleucel, approved in November 2024 for adults with relapsed or treatment-resistant B-cell ALL.
Other drug designs also exploit CD19. Blinatumomab is a bispecific molecule that physically bridges a patient’s T cells to CD19-carrying cancer cells, essentially forcing the immune system to attack them. Loncastuximab tesirine takes a different approach: it is an antibody that binds CD19 and delivers a toxic payload directly into the cancer cell. Both are used in patients whose disease has returned after earlier treatment lines.
When Cancer Cells Lose CD19
One significant challenge with CD19-targeted therapies is that cancer cells can evolve to escape them. Roughly 10 to 20 percent of ALL patients who receive CD19 CAR-T therapy experience what’s called a CD19-negative relapse, where the cancer returns but the cells no longer carry the protein the treatment was designed to find.
This happens through several mechanisms. The most direct involves mutations in the CD19 gene itself. Analysis of patients who relapsed after CAR-T therapy found that each patient had at least one distinctive insertion or deletion in the gene’s coding regions, often combined with loss of the second copy of the gene. These mutations produce a version of CD19 that either never reaches the cell surface or lacks the specific region the CAR-T cells were built to recognize.
Another route involves changes in how the CD19 gene is processed inside the cell. Reduced levels of a splicing factor called SRSF3 cause a critical segment of the gene to be skipped, resulting in a truncated protein that can’t anchor itself to the membrane. The therapeutic pressure essentially selects for any cancer cell that has found a way to hide CD19, transforming what may have been a tiny, pre-existing population of CD19-negative cells into the dominant clone driving the relapse. In some cases, the cancer undergoes a more dramatic shift, switching its entire lineage identity from B-cell to myeloid, silencing CD19 expression in the process.
Understanding these escape routes has prompted researchers to develop therapies that target multiple surface proteins simultaneously, pairing CD19 with markers like CD22 to reduce the odds that cancer cells can slip through by losing a single antigen.